Canaccord Genuity Rates Tango Therapeutics (TNGX) buy
Analyst John Newman reaffirms a buy rating on TNGX, raising the price target to $42, a 27.66% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Canaccord Genuity rated Tango Therapeutics, Inc. ($TNGX) "buy" with a $42 price target on June 11, 2026.
Since the rating, $TNGX is down 6.2% after 1 week, down 4.9% after 1 month and down 26.1% to date (from the $29.82 close on Jun 11, 2026).
TNGX
Tango Therapeutics, Inc.
Key Points
- Canaccord Genuity reiterated its buy rating on Tango Therapeutics, setting a new price target of $42, up from $42. This comes as the stock trades at $32.9.
- Canaccord Genuity's $42 price target implies 27.66% upside from Tango Therapeutics, Inc.'s ($TNGX) current $32.90 share price.
- Tango Therapeutics focuses on precision oncology, developing drugs for unmet medical needs, with its next earnings report due on November 4, 2026.
- The company has received favorable ratings from several analysts, with a consensus recommendation of strong buy and an average price target of approximately $45.18.
Get $TNGX trade alerts by text
We text you when insiders, Congress or big funds trade $TNGX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Tango Therapeutics, Inc. alert may contain errors. Disclosures
Canaccord Genuity Reaffirms Buy Rating on TNGX
On June 11, 2026, Canaccord Genuity reiterated its buy rating for Tango Therapeutics, Inc. (TNGX) on NasdaqGM, raising its price target to $42 from a previous target of $42. The stock closed at $32.9 on that day, making this an important update for investors.
Changes in Analyst Ratings
The change in rating reflects a confidence in Tango Therapeutics' growth potential. Canaccord Genuity has maintained its positive outlook, suggesting that the stock's current valuation may be an attractive opportunity for investors looking at the biotechnology sector.
Institutional Analyst Insights
Other analysts are also taking note of Tango Therapeutics. Notably, on October 16, 2026, William Blair initiated coverage with an Outperform rating. HC Wainwright & Co. maintained a Buy rating on August 18, 2026, with a target of $68, up from $66. Guggenheim also maintained a Buy rating with their target raised to $35 from $32 on August 12, 2026. These ratings indicate a positive sentiment towards the company's potential in the healthcare industry.
TNGX Stock Overview
The stock currently trades above its 50-day moving average of about $25.64 and is considerably above its 52-week low of $6.69. This performance suggests a strong upward trend in the stock price, which aligns with the analysts' positive outlook.
$TNGX price target
Tango Therapeutics, Inc. daily closes and this analyst's $42 target. Not advice.
Recent Earnings
Tango Therapeutics reported revenue of $53.8 million, but has not yet achieved profitability, with an EPS of -0.84. The next earnings report is set for November 4, 2026, which may provide further insights into the company's financial health and progress on its clinical trials.
Company Profile
Tango Therapeutics, founded in 2017 and based in Boston, MA, focuses on precision oncology. The company develops drugs aimed at specific patient populations with critical medical needs, particularly in treating various cancers. This reinforces the significance of the recent analyst upgrades, as clinical advancements can lead to increased interest from the investment community.
What's Ahead for Tango Therapeutics, Inc.
Investors will be keenly watching the upcoming earnings report on November 4, 2026, for updates on Tango's clinical trials and financial performance. Keep in mind that this analyst rating is based on past performance and expectations, and future developments will be key in shaping the company's trajectory.
Related Filing Alerts
Source: Canaccord Genuity's rating change on $TNGX (Jun 11, 2026). Written by software, not financial advice. How we make alerts